Next generation approach in advanced prostate cancer. meet the professor with elena castro

Acquisizione competenze di sistema:Tailored strategies for patients with brca or hrr mutations are increasingly important. Parp inhibitors like olaparib and rucaparib offer targeted treatment options, particularly for patients harboring these mutations. understanding the hrr status allows for a more refined therapeutic approach, guiding the use of parp inhibitors either as monotherapy or in combination with other treatments. the integration of these advanced approaches, from precision medicine to radiometabolic options, reflects the shift toward personalized, evidence-based care. This multi-modal strategy maximizes therapeutic outcomes while minimizing unnecessary toxicity, paving the way for more effective and patient-specific management of advanced prostate cancer. this event addresses all these topics to enhance knowledge and experience regarding innovative strategies for managing prostate cancer.